Abstract:Thrombotic thrombocytopenic purpura (TTP) is a particular form of thrombotic microangiopathy typically characterized by microangiopathic hemolytic anemia, profound peripheral thrombocytopenia, and a severe deficiency of the von Willebrand factor-cleaving protease ADAMTS13 (acronym for A Disintegrin And Metalloproteinase with ThromboSpondin-1 motifs [13th member of the family]). ADAMTS13 deficiency is usually severe (<10% of normal activity) and results from autoantibodies directed to ADAMTS13 (acquired TTP) or from biallelic mutations of the encoding gene. In some cases, acquired TTP occurs in association with specific conditions that must be identified for appropriate management: a HIV infection, a connective tissue disease, a pregnancy, a cancer or a treatment with antiplatelet agents. TTP requires a rapid diagnosis and an adapted management in emergency, which allows current remission rates of 80 to 90%. Maximal measures of resuscitation may be required. Daily sessions of therapeutical plasma exchange (TPE) until durable platelet count recovery remain the basis of management of acquired TTP. In the last few years, the anti-CD20 monoclonal antibody rituximab has been increasingly used in patients with a suboptimal response to standard treatment, such as those with refractory disease (∼10% of cases) or an exacerbation of the disease despite intensive TPE (∼50% of cases). Rituximab prevents 1-year but not long-term relapses. Further studies should specify the optimal schedule of rituximab administration and its role as a prophylactic treatment in asymptomatic patients with severe acquired ADAMTS13 deficiency that persists even in disease remission. In hereditary TTP, also known as Upshaw-Schulman syndrome (USS), a diagnosis early in life is mandatory. Prophylactic infusions of plasma should be performed in chronic relapsing forms to prevent long-term organ complications, which have to be assessed accurately and regularly. In the upcoming years, new targeted therapies evaluated through international trials should further improve the management of these diseases. Consensual guidelines for the treatment of very specific and rare situations (such as management during pregnancy in USS patients and prevention of relapses in chronic relapsing acquired TTP) should arise from the shared experience of national groups.

Refractory Thrombotic Thrombocytopenic Purpura in a Patient With Triple X Syndrome

Diagnosis and management of acquired thrombotic thrombocytopenic purpura in southeast China: a single center experience of 60 cases

Clopidogrel-induced refractory thrombotic thrombocytopenic purpura successfully treated with rituximab

Long-term remission induced by low-dose rituximab for relapsed and refractory thrombotic thrombocytopenic purpura: A report of two cases.

Plasmapheresis combined with rituximab treatment of a case of thrombotic thrombocytopenic purpura with Sjögren syndrome and renal impairment: A case report

Clinical Profile, Treatment and Outcome of Thrombotic Thrombocytopenia Purpura (TTP) in Rituximab Era- an Experience from Tertiary Care Centre from North India

Successful Treatment of Plasma Exchange-Refractory Thrombotic Thrombocytopenic Purpura with Rituximab: A Case Report

Primary immune thrombocytopenic purpura with exuberant oral manifestations in a patient with Turner syndrome

Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura

Clinical Analysis of 59 Patients with Thrombotic Thrombocytopenic Purpura

A case of trichodysplasia spinulosa related to ruxolitinib treated successfully with oral acitretin

Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic purpura in a patient with common variable immunodeficiency

A 2-Day-old Neonate with Hyperbilirubinemia and Thrombocytopenia

Therapeutic Plasma Exchange Management for a Pediatric Patient Presenting With Immune Thrombotic Thrombocytopenic Purpura in a Setting of Common Variable Immunodeficiency

A 21-Year-old Woman with Thrombotic Thrombocytopenic Purpura As Initial Symptom of Systemic Lupus Erythematosus and a Literature Review.

Small Bowel Ischemia and Ischemic Colitis Secondary to Thrombotic Thrombocytopenic Purpura in a Patient With Systemic Lupus Erythematous: A Rare Clinical Entity

Trichodysplasia spinulosa: Case reports and review of literature

Atypical Presentations of Pediatric-acquired Thrombotic Thrombocytopenic Purpura

Safety and efficacy of caplacizumab in a case of thrombotic thrombocytopenic purpura in the postpartum period

Thrombotic Thrombocytopenic Purpura in a Patient with Brucella Infection

Therapy of Hereditary Ttp with Adamts13 Deficiency - A Case Report and Review of the Literature.